PT1572178E - Tratamento de mastalgia com 4-hidroxi-tamoxifeno - Google Patents

Tratamento de mastalgia com 4-hidroxi-tamoxifeno

Info

Publication number
PT1572178E
PT1572178E PT03813146T PT03813146T PT1572178E PT 1572178 E PT1572178 E PT 1572178E PT 03813146 T PT03813146 T PT 03813146T PT 03813146 T PT03813146 T PT 03813146T PT 1572178 E PT1572178 E PT 1572178E
Authority
PT
Portugal
Prior art keywords
mastalgia
hydroxy
treatment
tamoxyphen
hydroxy tamoxifen
Prior art date
Application number
PT03813146T
Other languages
English (en)
Inventor
Bruno De Lignieres
Original Assignee
Besins Int Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Besins Int Lab filed Critical Besins Int Lab
Publication of PT1572178E publication Critical patent/PT1572178E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT03813146T 2002-12-18 2003-12-15 Tratamento de mastalgia com 4-hidroxi-tamoxifeno PT1572178E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43395902P 2002-12-18 2002-12-18

Publications (1)

Publication Number Publication Date
PT1572178E true PT1572178E (pt) 2006-09-29

Family

ID=32595255

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03813146T PT1572178E (pt) 2002-12-18 2003-12-15 Tratamento de mastalgia com 4-hidroxi-tamoxifeno

Country Status (15)

Country Link
US (1) US7786172B2 (pt)
EP (1) EP1572178B1 (pt)
JP (1) JP4938237B2 (pt)
AT (1) ATE324880T1 (pt)
AU (1) AU2003303033B2 (pt)
CA (1) CA2509660C (pt)
CY (1) CY1106131T1 (pt)
DE (1) DE60305068T2 (pt)
DK (1) DK1572178T3 (pt)
ES (1) ES2263072T3 (pt)
MX (1) MXPA05006526A (pt)
NZ (1) NZ540494A (pt)
PT (1) PT1572178E (pt)
SI (1) SI1572178T1 (pt)
WO (1) WO2004054557A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1952809B1 (en) * 2002-12-18 2017-08-02 Besins Healthcare Luxembourg SARL Formulations for the reduction of breast density with 4-Hydroxy Tamoxifen
ES2483896T3 (es) * 2003-04-01 2014-08-08 Besins Healthcare Luxembourg Sarl Prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen
NZ544031A (en) * 2003-06-09 2008-08-29 Univ Northwestern Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
EP1748770B1 (en) * 2004-03-22 2008-04-09 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US20050208139A1 (en) * 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579856A1 (en) * 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations
DK1799201T3 (da) * 2004-10-14 2009-03-30 Besins Int Lab 4-Hydroxy-tamoxifen gelformuleringer
DE202006021081U1 (de) * 2005-07-12 2012-05-08 Dmi Biosciences, Inc. Produkte zur Behandlung von Krankheiten
DK2326332T3 (da) 2009-06-22 2013-03-04 Dmi Acquistion Corp Fremgangsmåde til behandling af sygdomme
CN104968350A (zh) 2012-12-19 2015-10-07 安皮奥制药股份有限公司 疾病的治疗方法
SG11202002105WA (en) 2017-09-11 2020-04-29 Atossa Therapeutics Inc Methods for making and using endoxifen
JP7662204B2 (ja) 2019-07-03 2025-04-15 アトッサ・セラピューティクス・インコーポレイテッド エンドキシフェンの徐放性組成物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
ES2044860T3 (es) * 1987-04-21 1994-01-16 Heumann Pharma Gmbh & Co Estables aductos con disolventes de z-1-(p-beta-di-metil-amino-etoxi-fenil)-1-(p-hidroxi-fenil)-2-fenil-but-1-eno.
US5045553A (en) * 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
DE3836862A1 (de) 1988-10-27 1990-05-03 Schering Ag Mittel zur transdermalen applikation von steroidhormonen
US5189212A (en) * 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
TW218849B (pt) 1991-05-17 1994-01-11 Bristol Myers Squibb Co
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
US5720963A (en) * 1994-08-26 1998-02-24 Mary Kay Inc. Barrier disruption treatments for structurally deteriorated skin
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
IL120268A0 (en) * 1996-02-28 1997-06-10 Pfizer Use of (E)-1-[4'-(2-alkylaminoethioxy)phenyl]1-(3'-hydroxyphenyl)-2-phenylbut-1-enes in inhibiting pathological conditions
US6548491B2 (en) * 1997-12-24 2003-04-15 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US6013270A (en) * 1998-04-20 2000-01-11 The Procter & Gamble Company Skin care kit
CN100482216C (zh) * 1999-12-16 2009-04-29 德马全兹股份有限公司 氢氧根释放剂增强透皮渗透的用途
DE10033853A1 (de) 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
EP1177787A3 (en) 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
DE10054294A1 (de) 2000-11-02 2002-05-16 Heinrich Wieland Topische Behandlung bei der Mastalgie
ES2233570T3 (es) * 2000-11-30 2005-06-16 Pfizer Products Inc. Composicion que contiene agonistas/antagosnistas de estrogenos y testosterona para tratar un descenso en el nivel de la hormona testosterona.
CA2448235A1 (en) * 2001-07-31 2003-02-13 Pfizer Products Inc. Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
DK1317921T3 (da) * 2001-12-07 2009-12-21 Besins Mfg Belgium Farmaceutisk sammensætning i form af en gel eller oplösning med dihydrotestosteron, fremgangsmåde til fremstilling og anvendelser heraf
EP1952809B1 (en) * 2002-12-18 2017-08-02 Besins Healthcare Luxembourg SARL Formulations for the reduction of breast density with 4-Hydroxy Tamoxifen
ES2483896T3 (es) * 2003-04-01 2014-08-08 Besins Healthcare Luxembourg Sarl Prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen
NZ544031A (en) 2003-06-09 2008-08-29 Univ Northwestern Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US20050208139A1 (en) * 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579856A1 (en) 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations

Also Published As

Publication number Publication date
JP4938237B2 (ja) 2012-05-23
WO2004054557A2 (en) 2004-07-01
MXPA05006526A (es) 2006-02-17
EP1572178B1 (en) 2006-05-03
WO2004054557A3 (en) 2004-08-05
AU2003303033A1 (en) 2004-07-09
NZ540494A (en) 2007-05-31
HK1075403A1 (en) 2005-12-16
CY1106131T1 (el) 2011-06-08
AU2003303033B2 (en) 2009-06-04
DE60305068T2 (de) 2007-01-11
US20050032909A1 (en) 2005-02-10
EP1572178A2 (en) 2005-09-14
ES2263072T3 (es) 2006-12-01
US7786172B2 (en) 2010-08-31
CA2509660C (en) 2011-08-30
DE60305068D1 (de) 2006-06-08
ATE324880T1 (de) 2006-06-15
JP2006514949A (ja) 2006-05-18
SI1572178T1 (sl) 2006-10-31
DK1572178T3 (da) 2006-09-11
CA2509660A1 (en) 2004-07-01

Similar Documents

Publication Publication Date Title
WO2004054558A3 (en) Reduction of breast density with 4-hydroxy tamoxifen
IL258702B (en) A pump system for use with organ care systems
SI1572178T1 (sl) Zdravljenje mastalgije s 4-hidroksi-tamoksifenom
CZ2006579A3 (cs) Kožní mikroaktivační systém
EA200870019A1 (ru) Лактамовые соединения и способы их применения
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
BR0313371A (pt) Composto, uso de um composto e método de tratamento de doença
SE0101387D0 (sv) Novel compounds
CY1111177T1 (el) Ενωση φαινοθειαζινιου για επουλωση τραυματων
DE502007003850D1 (de) Gel zur Behandlung von Wunden
DE602004017871D1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
DE602004023183D1 (de) Gegen antikörper gerichtete photodynamische therapie
DE602006010442D1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von schmerzen
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
BRPI0415187A (pt) composição, método para matar bactérias, e, usos de composição e de bacteriófago
BRPI0519218A2 (pt) reduÇço do crescimento de cabelos ou pÊlos
ATE458495T1 (de) Therapeutische zubereitung für autoimmune erkrankungen
EA200500175A1 (ru) Соль морфин-6-глюкуронида
PL369331A1 (pl) Środek antyseptyczny do ran i błon śluzowych
ATE545421T1 (de) Pharmazeutisches präparat zur behandlung von parasitären tropenkrankheiten enthaltend diminazen-di-aceturat
BR0317925A (pt) Utilização de uma molécula ativa, composição cosmética e processo de tratamento da celulite
TNSN07139A1 (en) 4-hydroxy tamoxifen gel formulations
ITMI20041871A1 (it) Uso di santoreggia satureja montana o dei suoi estratti per la preparazione di medicamenti per il trattamento dell'eiaculazione precoce
NO20062138L (no) Anvendelse av ifenprodil i behandling av smerte
UA3134U (uk) Гель глибинної дії на капіляри і обмінні процеси "д. кавілін"